Statistics from Altmetric.com
Editor—Rett syndrome (RTT) (MIM 312750) is an X linked dominant neurodevelopmental disorder that occurs almost exclusively in females. Affected girls are considered to have a normal perinatal period followed by a period of regression, loss of acquired purposeful manual and speech skills, hand wringing, gait disturbance, and growth retardation.1 2
A gene for RTT has been identified in the Xq28 region which encodes the methyl-CpG binding protein 2 (MeCP2) involved in transcriptional silencing.3 4 This disorder most frequently occurs sporadically and results from a de novo mutation, although a few familial cases have been reported. Many studies5-16 have shown that the MECP2 gene is mutated in approximately 80% of patients with classical RTT and theMECP2 mutation spectrum includes missense, nonsense, and frameshift mutations, as well as larger rearrangements like deletions encompassing a few hundred bp.16 The failure to detect MECP2 mutations in the remaining 20% may indicate the presence of mutations in unexplored regions of the MECP2 gene, such as regulatory elements or non-coding regions, notably in the new first exon17 or in an additional RTT locus.
Here, we report for the first time mosaicism for a somaticMECP2 mutation found in two unrelated females affected with RTT. These two girls were diagnosed according to the international criteria of the Rett Syndrome Diagnostic Criteria Work Group.18
The first patient (case 1) is 13 years old. She suffers from classical Rett syndrome with 7/9 of the necessary criteria, 4/8 of the supportive criteria, and none of the exclusion criteria.18More specifically, she had a normal neonatal period and head circumference at birth and a phase of social withdrawal at the age of 12 months when she lost purposeful hand skills and developed stereotypic hand movements, ataxia, and apraxia. She suffered from breathing dysfunction and peripheral vasomotor disturbances. She had severely impaired development but acquired independent walking at the age of 24 months. However, she did not acquire microcephaly or develop epilepsy.
The second patient (case 2) was reported as an atypical case of RTT without any period of regression. Both mental and motor development were very slow. At the age of 4 years, she had acquired microcephaly (−2 SD) and had very limited ambulation, but her hand use was correct without hand wringing movements. She developed epilepsy and progressive scoliosis. She is a placid girl without useful speech but she communicates well by eye movements.
Methods and results
For case 1, an initial study on DNA extracted from a lymphoblastoid cell line by denaturing gradient gel electrophoresis (DGGE) and sequencing showed that she carried a 26 bp deletion starting at position 1165. To confirm this mutation, DNA was extracted from a fresh blood sample and the deletion was assessed by direct sequencing. Surprisingly and despite a careful examination of the sequence, we did not find the 26 bp deletion with DNA extracted from leucocytes. This sample was reanalysed by DGGE and heteroduplexes were detected while the homoduplex corresponding to the deleted band was absent (fig 1A). We confirmed this result by conformation sensitive gel electrophoresis (CSGE) analysis, which showed the heteroduplexes but not the mutant homoduplex (fig 1B). The results obtained from peripheral blood lymphocytes suggested mosaicism for a somatic mutation.
In order to determine the level of mosaicism, we used a semiquantitative approach based on fluorescent PCR. TheMECP2 gene exon 3 portion containing the deletion was PCR amplified, the reverse primer being conjugated to 6-FAM (6-carboxy-fluorescein). PCR products were analysed on an ABI 310 sequencer and peak areas were generated by ABI Genescan and Genotyper software. The ratio between the deleted and normal peak areas showed that only 36% of lymphocytes harboured the deletion, that is, 18% of X chromosomes bore the 26 bp deletion (fig 2A). This semiquantitative approach confirms that case 1 does have somatic mosaicism for the MECP2 deletion. The relatively low level of somatic mosaicism could explain the normal sequencing result. Thus, mosaicism was quantified in different tissues. DNA was extracted from buccal mucosa cells19 and hair bulb cells. 20 The level of mosaicism was about the same in buccal mucosa cells (30%) as in lymphocytes, but lower in hair bulbs cells (17.5%) (fig 2A).
On the basis of these results, we hypothesised that some patients with RTT may in fact carry a somatic mutation. Small deletions (from 7 to 170 bp) within the region between bp 1096 and 1165 of theMECP2 gene have been recurrently identified.5 7 9 10 12 15 16 They do not affect the two functional domains but result in the loss of one fifth of the protein. Interestingly, it has been shown that the deletion of the carboxy-terminal 63 amino acids of the MeCP2 protein impairs binding with the nucleosomal DNA during the transcription regulation process.21 These recurrent deletions may be the result of palindromic and quasipalindromic sequences within this region, which are believed to form secondary structures that render the region vulnerable to deletions. Therefore, using our fluorescent PCR approach, we reanalysed the 3′ region of the MECP2gene, between bp 1096 and 1165, in a cohort of 29 patients diagnosed as typical or atypical RTT; for these patients, we failed to detect any mutation using a bidirectional sequencing strategy of the entireMECP2 coding region. A second somatic mosaicism for a 27 bp deletion was identified in peripheral blood lymphocytes from case 2 with atypical RTT; the mosaicism rate was quantified with our fluorescent approach to be about 37% (fig 2B). We confirmed this result by CSGE analysis (fig 1B).
In both cases, numerical aberrations of the X chromosomes as a cause for the uncommon fluorescent PCR patterns were excluded by the presence of a normal 46,XX karyotype.
These two patients show a similar deletion with an equivalent mosaicism rate in blood, but a distinct clinical presentation. X inactivation study on proband 1 with typical Rett syndrome showed a random pattern of inactivation in the peripheral blood. Although the results have to be extrapolated from the peripheral blood cells, it would suggest that in the brain the majority of mutated X chromosomes may remain active in the girl with classical Rett syndrome. Our results illustrate clearly once again the difficulty in establishing a correlation between genotype and phenotype in RTT.
Recently, a boy with a mosaic mutation has been described.22 To our knowledge, we show for the first time that somatic mosaicism for MECP2 mutation in girls is not infrequent (two somatic mutations on 102 putative RTT cases studied) and may cause different phenotypes. These clinical and molecular findings suggest that multiple forms of mosaicism (X inactivation mosaicism and somatic mosaicism) may be present in a single patient with RTT. Mosaicism has been documented for chromosomal abnormalities, mitochondrial mutations, triplet repeats,23and in a growing number of dominant and recessive X linked gene disorders, such as Duchenne muscular dystrophy,24haemophilia B,25 Conradi-Hünermann-Happle syndrome,26 and double cortex/lissencephaly syndrome.27 Because a proportion of cells carry the mutation not only in blood but also in tissues deriving from other cell lineages, it must be assumed that the mutation occurred very early during embryogenesis.
Finally, the detection of mosaic mutation depends mainly on the method used for the identification of mutations within theMECP2 gene. Nowadays, the method of choice for identifying deleterious mutations relies on direct DNA sequencing. The ability of this method to detect mosaic mutations is poor, which is particularly true when the mosaicism rate is low. Our findings underline the need for at least two complementary approaches, such as methods based on heteroduplex analysis and sequencing, for an efficient screening of the MECP2 gene.
We thank Dr Deblay for critical advice, Dr Florence Rousselet for her technical contribution, and l'Association Française du Syndrome de Rett, l'Association Française contre les myopathies, and the Ministère de l'Education Nationale, de la Recherche et de la Technologie for their financial support.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.